EUVIMEDEUVIMED entdecken
VergleichsstudieKlinische Studie

Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial

Meixi Liu, Chao Ren, Haiqiong Zhang, Yuwei Zhang, Zhenghai Huang, Ru Jia, Yuejuan Cheng, Chunmei Bai, Qiang Xu, Wenjia Zhu, Li Huo iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06790-y ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Meixi Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College …. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, CAMS innovation fund for medical science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: 18F-labelled somatostatin receptor (SSTR) analogs offer several advantages over 68Ga in terms of yield, cost, spatial resolution and detection rate. This study presents an interim analysis of a prospective trial designed to assess the safety, biodistribution and dosimetry of [18F]AlF-NOTA-LM3, and compare its diagnostic efficacy and clinical management outcomes with [68Ga]Ga-DOTATATE or [68Ga]Ga-NODAGA-LM3 in patients with well-differentiated NETs. METHODS: Twenty-one patients with histologically confirmed well-differentiated neuroendocrine tumors (G1 and G2) were prospectively recruited. The first eight patients underwent serial PET scans at 5, 15, 30, 45, 60, and 120 min after [18F]AlF-NOTA-LM3 injection to assess biodistribution and dosimetry. The remaining patients underwent whole-body PET/CT scans. [18F]AlF-NOTA-LM3 and [68Ga]Ga-DOTATATE PET/CT were done within a week, with a minimum 24-hour interval between the two scans. Focal uptake above the surrounding background activity and could not be explained by physiologic uptake was considered lesions of NETs. Lesion number, tumor uptake, and tumor-to-background ratio (TBR) were compared. In patients with discrepant findings, the size of the smallest lesions (measured on coregistered CT) detected on [68Ga]Ga-DOTATATE and [18F]AlF-NOTA-LM3 was compared. RESULTS: [18F]AlF-NOTA-LM3 was safe and well-tolerated. Physiological uptake of [18F]AlF-NOTA-LM3 was significantly lower than that of [68Ga]Ga-DOTATATE in abdominal organs and bone marrow, but higher in blood pool and lung. The mean effective dose was 0.024 ± 0.014 mSv/MBq. [18F]AlF-NOTA-LM3 detected significantly more liver lesions (457 vs. 291, P = 0.006) and lymph node lesions (30 vs. 22, P = 0.011) compared to [68Ga]Ga-DOTATATE. The tumor uptake was comparable, but TBR was significantly higher with [18F]AlF-NOTA-LM3 for lesions from all sites except for the duodenum. The size of the minimum liver lesions (0.54 ± 0.15 vs. 1.01 ± 0.49, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOrganometallic CompoundsHumansMaleFemaleMiddle AgedProspective StudiesAgedTissue DistributionAdultRadiometryPositron Emission Tomography Computed TomographySafetyRadiopharmaceuticalsHeterocyclic Compounds, 1-RingAcetates

Stichwörter der Autor:innen

AntagonistNeuroendocrine tumorSomatostatin receptor[18F]AlF-NOTA-LM3[68Ga]Ga-DOTATATE

Substanzen

gallium Ga 68 dotatateOrganometallic Compounds1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneRadiopharmaceuticalsHeterocyclic Compounds, 1-Ring1,4,7-triazacyclononane-N,N',N''-triacetic acidAcetates

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical…
  • Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, Beijing, 100730, China.
  • Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, 100730, China.

ORCID-Profile: Li Huo

Förderung

  • the National Natural Science Foundation of China
  • National High Level Hospital Clinical Research Funding
  • CAMS innovation fund for medical science
  • National Key Research and Development Program of China
  • CAMS fund for Rare Diseases Research
  • Tsinghua university and PUMCH joint fund
  • China Postdoctoral Science Foundation

Zitieren

APA

Liu, M., Ren, C., Zhang, H., Zhang, Y., Huang, Z., Jia, R., Cheng, Y., Bai, C., Xu, Q., Zhu, W., & Huo, L. (2024). Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06790-y

Vancouver

Liu M, Ren C, Zhang H, Zhang Y, Huang Z, Jia R, et al. Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06790-y

BibTeX
@article{Liu2024,
  author = {Liu, Meixi and Ren, Chao and Zhang, Haiqiong and Zhang, Yuwei and Huang, Zhenghai and Jia, Ru and Cheng, Yuejuan and Bai, Chunmei and Xu, Qiang and Zhu, Wenjia and Huo, Li},
  title = {Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NOTA-LM3 and head-to-head comparison with [68Ga]Ga-DOTATATE in patients with well-differentiated neuroendocrine tumors: an interim analysis of a prospective trial},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06790-y}
}
Kostenlos starten →